CompletedNot Applicable

Pulsed Field Ablation for Paroxysmal Supraventricular Tachycardia（PSVT）

China10 participantsStarted 2022-10-11

Plain-language summary

The purpose of this study was to explore the safety and efficacy of a Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the treatment of Paroxysmal Supraventricular Tachycardia.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with symptomatic paroxysmal supraventricular tachycardia including:Atrioventricular nodal re-entrant tachycardia, Atrioventricular arrhythmias;
✓. Willingness to undergo an evaluation to validate the requirements of the protocol.
✓. Voluntary signed informed consent and willingness to undergo the tests and procedures required by the protocol.

Exclusion criteria

✕. Patients with structural heart disease
✕. History of any cardiac surgery
✕. Failure of prior ablation of PSVT
✕. Presence of any implantation, such as artificial valves, permanent pacemakers, etc
✕. Patients with active systemic infections
✕. Any condition contraindicating septal puncture or retrograde transaortic approach for procedures
✕. Any condition contraindicating heparin or aspirin
✕. Patients with advanced malignant tumor

What they're measuring

Immediate ablation success rate

Timeframe: 15 minutes post ablation

Rate of Treatment Success at 6-Month Post-Procedure

Timeframe: Refers to the postoperative phase after 6 months postoperatively

Trial details

NCT IDNCT05770921

SponsorNingbo No. 1 Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-02-01

View on ClinicalTrials.gov More Paroxysmal Supraventricular Tachycardia trials